Business
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative
About this update from Tela Bio, Inc.
[{"type":"text","content":"MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (\"TELA Bio\"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered revenue of $20.9 million in the fourth quarter and $80.3 million for the full year 2025, an 18% and 16% increase, respectively, from the corresponding periods of 2024;Expanded the sales force to 88 quota-carrying representatives as of today under the leadership of commercial management added at midyear;Announcing promotion of Howard Langstein, MD, FACS to Chief Medical Officer, effective March 1, 2026; andClosed on a credit facility for up to $70.0 million from Perceptive Advisors (“Perceptive”). The Perceptive credit facility consists of an initial loan of $60.0 million received at closing and an additional $10.0 million that can be drawn at our option by April 30, 2027, upon satisfaction of certain conditions, including, but not limited to, the achievement of net revenue thresholds. \"We closed 2025 with our strongest quarterly revenue on record, delivering $20.9 million and 18% growth over Q4 2024 while holding operating expenses essentially flat for the year, demonstrating the operating leverage we expect to continue to see in the years ahead,\" said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. \"Over the last six months we strengthened our leadership and upgraded the commercial field organization. Today, the team we have assembled is the best we have ever had, with 89 revenue-generating reps in place to drive greater penetration into key markets throughout the U.S. Based on the current ramp of tenured reps in the field, we are confident in the team’s ability to deliver at least 8% revenue growth in 2026, and keep us on a path to profitability without the need to raise additional capital.” Fourth Quarter 2025 Financial Results Revenue was $20.9 million in the fourth quarter of 2025, an increase of 18% compared to the same period in 2024. The increase was driven by the addition of new customers, the U.S. launch of the larger-sized new OviTex PRS product configuration and an increase in international sales. This growth was partially offset by a shift in hernia product mix toward smaller-size...